We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

18 hedge funds and large institutions have $544K invested in Scinai Immunotherapeutics in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

29% more funds holding

Funds holding: 14 → 18 (+4)

0% less ownership

Funds ownership: 0% → 0% (-0%)

31% less capital invested

Capital invested by funds: $789K → $544K (-$245K)

Holders
18
Holders Change
+4
Holders Change %
+28.57%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
3
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$81.7K
2
Citadel Advisors
Citadel Advisors
Florida
+$61.3K
3
Millennium Management
Millennium Management
New York
+$29.3K
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$7.26K
5
Morgan Stanley
Morgan Stanley
New York
+$5.81K

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$200K
2
ECM
ExodusPoint Capital Management
New York
-$74K
3
TSS
Two Sigma Securities
New York
-$38.5K
4
JP Morgan Chase
JP Morgan Chase
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
1
Susquehanna International Group
Pennsylvania
$94K +$81.7K +563 New
Envestnet Asset Management
2
Envestnet Asset Management
Illinois
$83K – – –
TPWA
3
TRUE Private Wealth Advisors
Oregon
$79K +$5.08K +35 +8%
Morgan Stanley
4
Morgan Stanley
New York
$79K +$5.81K +40 +9%
Citadel Advisors
5
Citadel Advisors
Florida
$70K +$61.3K +422 New
TSS
6
Two Sigma Securities
New York
$38K -$38.5K -265 -54%
Millennium Management
7
Millennium Management
New York
$34K +$29.3K +202 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$22K – – –
UBS Group
9
UBS Group
Switzerland
$17K +$4.5K +31 +43%
BNP Paribas Financial Markets
10
BNP Paribas Financial Markets
France
$8.3K +$7.26K +50 New
Credit Agricole
11
Credit Agricole
France
$7K – – –
Royal Bank of Canada
12
Royal Bank of Canada
Ontario, Canada
$4K – – –
Citigroup
13
Citigroup
New York
$3K +$2.9K +20 New
CAPTRUST Financial Advisors
14
CAPTRUST Financial Advisors
North Carolina
$2K – – –
TRCT
15
Tower Research Capital (TRC)
New York
$2K +$1.74K +12 New
GRP
16
Global Retirement Partners
California
$1K +$726 +5 New
APC
17
Aspire Private Capital
North Carolina
$1K +$1.16K +8 New
State Street
18
State Street
Massachusetts
– -$200K -852 Closed
ECM
19
ExodusPoint Capital Management
New York
– -$74K -315 Closed
JP Morgan Chase
20
JP Morgan Chase
New York
– -$1K -3 Closed

SCNI Hedge Fund Activity: Q1 2022 in Review

18 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q1 2022, worth a combined $544K — down 31% from $789K a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new SCNI positions and 3 closed out — a net gain of 5 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $81.7K. The largest seller was State Street, exiting entirely with an estimated $200K sold.

  • 18 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q1 2022, up from 14 in Q4 2021.
  • Funds reported $544K of Scinai Immunotherapeutics stock for Q1 2022, down 31% quarter-over-quarter.
  • 8 funds opened new Scinai Immunotherapeutics positions in Q1 2022 and 3 closed out, a net change of +5 holders.
  • The largest Scinai Immunotherapeutics buyer in Q1 2022 was Susquehanna International Group, an estimated $81.7K added.
  • The largest Scinai Immunotherapeutics seller in Q1 2022 was State Street, an estimated $200K sold.

Based on aggregated 13F filings for Q1 2022.